Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.52 |
| ▸ | ME2 | P23368 | 2/20 | 0.45 |
| ▸ | ME1 | P48163 | 2/20 | 0.45 |
| ▸ | ME3 | Q16798 | 2/20 | 0.45 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | DRD2 | P14416 | 3/20 | 0.42 |
| ▸ | CNR2 | P34972 | 1/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | AKT1 | P31749 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | HTR2A | P28223 | 1/20 | 0.41 |
| ▸ | HTR2C | P28335 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
| ▸ | DRD3 | P35462 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2549668 | 1.00 | PANK3 (0.52) | PANK3ME2ME1ME3TRPV1 | |
| SCHEMBL2247600 | 0.89 | MMP1 (0.55) | PANK3ME2ME1ME3TRPV1 | |
| SCHEMBL2552096 | 0.89 | MMP1 (0.55) | PANK3ME2ME1ME3TRPV1 | |
| SCHEMBL2552324 | 0.88 | PANK3 (0.50) | PANK3ME2ME1ME3PPARG | |
| SCHEMBL2248916 | 0.88 | PANK3 (0.50) | PANK3ME2ME1ME3PPARG | |
| SCHEMBL2246283 | 0.83 | GRM1 (0.41) | PANK3ALDH1A1 | |
| SCHEMBL2252819 | 0.83 | GRM1 (0.41) | PANK3ALDH1A1 | |
| SCHEMBL2252745 | 0.83 | ALDH1A1 (0.58) | PANK3CYP3A4ALDH1A1 | |
| SCHEMBL2249019 | 0.83 | ALDH1A1 (0.58) | PANK3CYP3A4ALDH1A1 | |
| SCHEMBL2246989 | 0.78 | MAPK1 (0.47) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | claimed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | claimed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | claimed |
| US-8247437-B2 | N-hydroxyamide derivatives and use thereof | MERCK SERONO SA (CH) | 2012-08-21 | — | — | US | disclosed |
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2011-10-27 | — | — | US | disclosed |
| US-8008302-B2 | ((2S,3S) N,2-dihydroxy-5-methyl-3-{[4-(2-pyridinyl)-1-piperazinyl]carbonyl}hexanamide; for treatment and/or prevention of disorders related to autoimmune disorders and/or inflammatory diseases, cardiovascular diseases, neurodegenerative diseases, stroke, cancer, pre-term labor, endometriosis | MERCK SERONO SA (CH) | 2011-08-30 | — | — | US | disclosed |
| EP-1771421-B1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | SERONO LAB (CH) | 2009-04-29 | — | — | EP | disclosed |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (NL) | 2008-01-24 | — | — | US | disclosed |
| EP-1771421-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | Applied Research Systems ARS Holding N.V. (AN) | 2007-04-11 | — | — | EP | disclosed |
| WO-2006010751-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 2006-02-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263628-A1 | N-HYDROXYAMIDE DERIVATIVES AND USE THEREOF | HNMT, HCAR2, HPGD | PANK3 3763/4885ME2 235/4885ME1 2306/4885 |
| US-20080021028-A1 | N-Hydroxyamide Derivatives and Use Thereof | HCAR2, HNMT, HPGD | PANK3 3905/4885ME2 227/4885ME1 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.